STOUGHTON, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain, today announced that management will present at the following investor conferences in November:

• The Jefferies Healthcare Conference on Wednesday, November 14th at 4:00 p.m. GMT in London
• The Piper Jaffray Healthcare Conference on Tuesday, November 27th at 2:30 p.m. EST in New York City

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain and our communities.

About Xtampza ER

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact: Alex Dasalla[email protected]

Source: Collegium Pharmaceutical, Inc.

Press Releases